Mezzion Pharma Co. Ltd   Report issue

For profit Phase 3
Founded: Seoul Korea, Republic of (2002)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2014
NCT02201342
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Mezzion Pharma Co. Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

udenafil (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1